Arrowhead Pharmaceuticals: Targeting the Genome Rocket: How to Reprogram Medicine
Reading Time: 3 minutes
Arrowhead Pharmaceuticals develops highly precise RNAi therapeutics that directly target and silence disease-causing genes at their genetic origin. The company is currently transforming from a pure research entity into a commercial biopharma provider with its own product revenues through the utilization of a broad pipeline. In addition to established partnerships with global pharmaceutical giants, Arrowhead addresses lucrative multi-billion markets with innovative treatments in the cardio-metabolic sector. The US biotech company Arrowhead...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
